ADALTA LAUNCHES $10M IPO TO DRIVE FIBROSIS TREATMENT

Written on the 11 July 2016

ADALTA LAUNCHES $10M IPO TO DRIVE FIBROSIS TREATMENT

BIOTECHNOLOGY company AdAlta has launched an IPO to raise $10 million to fund clinical studies into its fibrosis treatment.

The Melbourne-based company's lead component AD-114 produces proteins which mimic the shape of shark antibodies and engineers their key stability features to create i-bodies.

The i-bodies will be used to develop a pipeline of drugs to treat fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF).

AdAlta CEO Sam Cobb says current therapies have limited efficacy and the ASX tilt will help the company deliver a solution.

"The IPO funding will allow AdAlta to develop AD-114 to a point that will be ready for licensing to a major pharmaceutical company," Cobb says.

"There is heightened global interest in promising new treatments for fibrosis as well as for the new generations of antibody technologies.

"We also plan to expand our own internal development pipeline of novel proprietary i-body drug candidates generating sustainable future licensing opportunities."

AdAlta plans to capitalise on global pharmaceutical companies seeking to access innovative new drug candidates to fill their pipelines.

The company's strategy is to partner its i-body technology platform to generate early revenues, as well as license its i-body drugs at an early stage.

Cobb says AdAlta has no plans to commercialise new drugs based on its technology, which would delay returns to investors by years.

"Proceeds from the offer will be deployed to expedite our first candidate into Phase 1 human clinical trials and extend the technology into other diseases," she says.

"Our strategy is to license this drug candidate on completion of the planned Phase 1 clinical studies proposed in the offer.

"In addition, AdAlta intends to license or partner the i-body technology platform for drug discovery with pharmaceutical and biotechnology companies, with the objective of earning up front, milestone payments and licensing revenues.

"Our business model of partnering our i-body library and early licensing of our proprietary i-body drug candidates offers both short-term and medium-term revenue opportunities and spreads the risk."

AdAlta was founded in 2007 based on discoveries made from scientists in the Co-operative Research Centre for Diagnostics, including CSIRO and La Trobe University.

Cornerstone investors, including early stage venture capital firm Yuuwa Capital, will subscribe for $7 million in the IPO.

The company plans to raise at least $8 million at 25 cents a share under the proposed ticker AAB.

 


Latest News

SUPREME COURT ORDERS OCTAVIAR GROUP TO WIND UP

THE Queensland Supreme Court has ordered the Octaviar Group of companies (formerly known as MFS Group) to be wound...

CEOS BRAVE THE COLD TO RAISE $1.4 MILLION FOR THE HOMELESS

MORE than 400 executives confronted the cold last night in the annual Vinnies CEO sleepout, which took place benea...

JENNIFER WESTACOTT ON BANK TAX: IT EXPOSES GOVERNMENT "DESPERATION"

South Australia's new bank levy exposes the desperation of a government that is unable to get its own budget and ...

BASKETBALL'S COMEBACK CONTINUES WITH NBL CLUBS TO FACE OFF AGAINST CHINA'S NATIONAL TEAM

THE RESURGENCE of Australia's National Basketball League (NBL) continues with China's national team to play t...

Related News

BASKETBALL'S COMEBACK CONTINUES WITH NBL CLUBS TO FACE OFF AGAINST CHINA'S NATIONAL TEAM

THE RESURGENCE of Australia's National Basketball League (NBL) continues with China's national team to play t...

DOMESTIC TOURISM IN AUSTRALIA BREAKS RECORDS, INJECTS $61.7 BILLION INTO NATIONAL ECONOMY

DOMESTIC Australian tourists have spent a record breaking $61.7 billion on intra and interstate travel this year, acc...

THE DOCTORS WHO PLUNGED INTO THE SHARK TANK AND SURVIVED WITH A $500,000 INVESTMENT

THEIR mission is to change the face of cancer care with an app that empowers and connects patients and care givers...

IMF BRACES FOR BIG LOSS FOLLOWING WITHDRAWAL FROM SPOTLESS CLASS ACTION

LITIGATION fund IMF Bentham (ASX: IMF) is set to lose as much as half a million dollars after it ceases funding one o...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter